203 related articles for article (PubMed ID: 35011611)
1. Altered Ca
Buks R; Dagher T; Rotordam MG; Monedero Alonso D; Cochet S; Gautier EF; Chafey P; Cassinat B; Kiladjian JJ; Becker N; Plo I; Egée S; El Nemer W
Cells; 2021 Dec; 11(1):. PubMed ID: 35011611
[TBL] [Abstract][Full Text] [Related]
2. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
4. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.
Duek A; Lundberg P; Shimizu T; Grisouard J; Karow A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC
Blood; 2014 Jun; 123(25):3943-50. PubMed ID: 24820309
[TBL] [Abstract][Full Text] [Related]
5. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.
Laubach JP; Fu P; Jiang X; Salter KH; Potti A; Arcasoy MO
Exp Hematol; 2009 Dec; 37(12):1411-22. PubMed ID: 19815050
[TBL] [Abstract][Full Text] [Related]
6. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
[TBL] [Abstract][Full Text] [Related]
8. Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells.
Zeuner A; Pedini F; Signore M; Ruscio G; Messina C; Tafuri A; Girelli G; Peschle C; De Maria R
Blood; 2006 May; 107(9):3495-502. PubMed ID: 16384930
[TBL] [Abstract][Full Text] [Related]
9. The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera.
Falchi M; Varricchio L; Martelli F; Marra M; Picconi O; Tafuri A; Girelli G; Uversky VN; Migliaccio AR
Exp Hematol; 2017 Jun; 50():53-76. PubMed ID: 28232234
[TBL] [Abstract][Full Text] [Related]
10. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.
Shi J; Yuan B; Hu W; Lodish H
Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563
[TBL] [Abstract][Full Text] [Related]
11. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
12. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
[TBL] [Abstract][Full Text] [Related]
13. JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway.
De Grandis M; Cambot M; Wautier MP; Cassinat B; Chomienne C; Colin Y; Wautier JL; Le Van Kim C; El Nemer W
Blood; 2013 Jan; 121(4):658-65. PubMed ID: 23160466
[TBL] [Abstract][Full Text] [Related]
14. Abnormal adhesion of red blood cells in polycythemia vera: a prothrombotic effect?
El Nemer W; De Grandis M; Brusson M
Thromb Res; 2014 May; 133 Suppl 2():S107-11. PubMed ID: 24862129
[TBL] [Abstract][Full Text] [Related]
15. Distinct effects of V617F and exon12-mutated JAK2 expressions on erythropoiesis in a human induced pluripotent stem cell (iPSC)-based model.
Nilsri N; Jangprasert P; Pawinwongchai J; Israsena N; Rojnuckarin P
Sci Rep; 2021 Mar; 11(1):5255. PubMed ID: 33664283
[TBL] [Abstract][Full Text] [Related]
16. Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage.
da Costa Reis Monte-Mór B; Plo I; da Cunha AF; Costa GG; de Albuquerque DM; Jedidi A; Villeval JL; Badaoui S; Lorand-Metze I; Pagnano KB; Saad ST; Vainchenker W; Costa FF
Leukemia; 2009 Jan; 23(1):144-52. PubMed ID: 18843287
[TBL] [Abstract][Full Text] [Related]
17. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S
Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053
[TBL] [Abstract][Full Text] [Related]
18. Imatinib effect on growth and signal transduction in polycythemia vera.
Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
[TBL] [Abstract][Full Text] [Related]
19. Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.
Hattori N; Fukuchi K; Nakashima H; Maeda T; Adachi D; Saito B; Yanagisawa K; Matsuda I; Nakamaki T; Gomi K; Tomoyasu S
Int J Hematol; 2008 Sep; 88(2):181-188. PubMed ID: 18612778
[TBL] [Abstract][Full Text] [Related]
20. Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.
Tsuruta-Kishino T; Koya J; Kataoka K; Narukawa K; Sumitomo Y; Kobayashi H; Sato T; Kurokawa M
Oncogene; 2017 Jun; 36(23):3300-3311. PubMed ID: 28068330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
